Intracerebral Hemorrhage
Conditions
Interventions
Experimental group:Minocycline treatment+medical therapy
Control group :Medical therapy
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, regardless of gender; 2. Supratentorial ICH confirmed by brain CT scan; 3. No disability in the community before ICH (premorbid mRS= 6 and single-limb motor item score >= 2; 5. GCS score >= 6; 6. Able to initiate the first dose of minocycline within 24 hours of onset; 7. Signed and dated informed consent.
Exclusion criteria
Exclusion criteria: 1. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs; 2. Allergy to tetracycline antibiotics; 3. Use of vitamin A derivatives or steroid therapy within the past 3 months; 4. Concomitant infection requiring antibiotic treatment at admission; 5. Planned surgical intervention; 6. Life expectancy of less than 6 months due to comorbid conditions; 7. Severe hepatic and renal dysfunction, or AST and/or ALT >3 times the upper limit of reference range, or serum creatinine >265 µmol/L (> 3 mg/dL); 8. Bleeding tendency, including heparin use within the past 48 hours (APTT >= 35 s), oral warfarin (INR > 2), platelet count < 100 × 10^9/L, or hereditary hemorrhagic diseases; 9. Known pregnancy or breastfeeding; 10. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; 11. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen; 12. Patients unsuitable for enrollment in the clinical trial according to the investigator’s discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with favorable functional outcomes, defined as mRS 0–2 at 180 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with an mRS score of 0-1 at 180 days;The proportion of patients with favorable functional outcome (mRS score of 0-2) at 90 days;The proportion of patients with an mRS score of 0-1 at 90 days;The distribution of mRS scores at 90 days and 180 days;The NIHSS scores after 7 days of treatment; | — |
Countries
China
Contacts
Public ContactYi Yang
The First Hospital of Jilin University
Outcome results
None listed